EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

M6A-modified lncRNA FAM83H-AS1 promotes colorectal cancer progression through PTBP1

Xiao-Jing Luo, Yun-Xin Lu, Yun Wang, Runjie Huang, Jia Liu, Ying Jin, Ze-Kun Liu, Ze-Xian Liu, Qi-Tao Huang, Heng-Ying Pu, Zhao-Lei Zeng, Ruihua Xu und 2 weitere

Cancer Letters · 2024-08 · 598 · 217085

DOI: 10.1016/j.canlet.2024.217085 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Letters, 2024-08. Verfasst von Xiao-Jing Luo und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Researc…. Hauptthemen laut MEDLINE: Polypyrimidine Tract-Binding Protein, RNA, Long Noncoding, Colorectal Neoplasms, Heterogeneous-Nuclear Ribonucleoproteins. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

LncRNA plays a crucial role in cancer progression and targeting, but it has been difficult to identify the critical lncRNAs involved in colorectal cancer (CRC) progression. We identified FAM83H-AS1 as a tumor-promoting associated lncRNA using 21 pairs of stage IV CRC tissues and adjacent normal tissues. In vitro and in vivo experiments revealed that knockdown of FAM83H-AS1 in CRC cells inhibited tumor proliferation and metastasis, and vice versa. M6A modification is critical for FAM83H-AS1 RNA stability through the writer METTL3 and the readers IGF2BP2/IGFBP3. PTBP1-an RNA binding protein-is responsible for the FAM83H-AS1 function in CRC. T4 (1770-2440 nt) and T5 (2440-2743 nt) on exon 4 of FAM83H-AS1 provide a platform for PTBP1 RRM2 interactions. Our results demonstrated that m6A modification dysregulated the FAM83H-AS1 oncogenic role by phosphorylated PTBP1 on its RNA splicing effect. In patient-derived xenograft models, ASO-FAM83H-AS1 significantly suppressed the growth of gastrointestinal (GI) tumors, not only CRC but also GC and ESCC. The combination of ASO-FAM83H-AS1 and oxaliplatin/cisplatin significantly suppressed tumor growth compared with treatment with either agent alone. Notably, there was pathological complete response in all these three GI cancers. Our findings suggest that FAM83H-AS1 targeted therapy would benefit patients primarily receiving platinum-based therapy in GI cancers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Polypyrimidine Tract-Binding ProteinRNA, Long NoncodingColorectal NeoplasmsHeterogeneous-Nuclear RibonucleoproteinsCell ProliferationDisease ProgressionMethyltransferasesGene Expression Regulation, NeoplasticHumansAnimalsMiceCell Line, TumorAdenosineMaleFemaleXenograft Model Antitumor AssaysMice, NudeRNA StabilityCell MovementMice, Inbred BALB CRibonucleoside Diphosphate ReductaseRNA-Binding Proteins

Stichwörter der Autor:innen

CRCFAM83H-AS1PTBP1RNA splicingm6A modification

Substanzen

Polypyrimidine Tract-Binding ProteinRNA, Long NoncodingPTBP1 protein, humanHeterogeneous-Nuclear RibonucleoproteinsMethyltransferasesMETTL3 protein, humanN-methyladenosineAdenosineIGF2BP2 protein, humanribonucleotide reductase M2

Autor:innen und Institutionen

  • Department of Pathology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, 510060, PR China.
  • Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, 510060, PR China.
  • Department of Radiology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, 510060, PR China.
  • State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, 510060, PR China.
  • Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, 510060, PR China; Research Unit…
  • State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, 510060, PR China. Electronic address: zhaoqi@sysucc.org.cn.

Zitieren

APA

Luo, X. J., Lu, Y. X., Wang, Y., Huang, R., Liu, J., Jin, Y., Liu, Z. K., Liu, Z. X., Huang, Q. T., Pu, H. Y., Zeng, Z. L., Xu, R., Zhao, Q., & Wu, Q. N. (2024). M6A-modified lncRNA FAM83H-AS1 promotes colorectal cancer progression through PTBP1. Cancer Letters, 598, 217085. https://doi.org/10.1016/j.canlet.2024.217085

Vancouver

Luo XJ, Lu YX, Wang Y, Huang R, Liu J, Jin Y, et al. M6A-modified lncRNA FAM83H-AS1 promotes colorectal cancer progression through PTBP1. Cancer Letters. 2024;598:217085. doi:10.1016/j.canlet.2024.217085

BibTeX
@article{Luo2024,
  author = {Luo, Xiao-Jing and Lu, Yun-Xin and Wang, Yun and Huang, Runjie and Liu, Jia and Jin, Ying and Liu, Ze-Kun and Liu, Ze-Xian and Huang, Qi-Tao and Pu, Heng-Ying and Zeng, Zhao-Lei and Xu, Ruihua and Zhao, Qi and Wu, Qi-Nian},
  title = {M6A-modified lncRNA FAM83H-AS1 promotes colorectal cancer progression through PTBP1},
  journal = {Cancer Letters},
  year = {2024},
  volume = {598},
  pages = {217085},
  doi = {10.1016/j.canlet.2024.217085}
}
Kostenlos starten →